Celcuity's stock experienced a significant drop on Wednesday following the announcement that the biotech company would be postponing the release of its recently approved breast cancer therapy until the third quarter. This delay resulted in a double-digit decrease in their stock value, highlighting the challenges they are currently facing despite securing their first FDA approval. The latest setback raises concerns about the company's performance and its ability to meet market expectations.